Use of Cosmetic Facial Injectables After Facial Aesthetic Surgery.

Abstract

Over the last 2 decades, both invasive and minimally invasive aesthetic procedures have proliferated. Aesthetic surgeons often recommend injectable treatments after cosmetic facial surgery for multiple reasons. However, literature is lacking on how cosmetic surgery affects postoperative facial injectable use. The aim of this study was to identify predictors of facial injectable use after cosmetic facial surgery. All adult patients operated on by a single surgeon between 2013 and 2021 were retrospectively reviewed. Patients who had any of the following cosmetic facial surgeries were included: rhytidectomy, blepharoplasty, rhinoplasty, or genioplasty. Patient demographics, clinical history, intraoperative factors, and use of cosmetic facial injectables (neurotoxin, facial fillers, deoxycholic acid, poly-l-lactic acid) were recorded. A total of 227 patients who underwent facial cosmetic surgery were reviewed, of whom 158 were included. Of these, 89 patients had rhytidectomy (56.3%), 112 had blepharoplasty (70.9%), 28 had rhinoplasty (17.7%), and 7 had genioplasty (4.4%). Injectables were administered to 44.3% of patients after their surgery (n = 73), compared with only 17.7% before surgery (n = 28) (P < 0.001). The most common postoperative injectables were neurotoxins (48.5%) and facial fillers (46.0%), followed by deoxycholic acid (2.7%) and poly-l-lactic acid (2.7%). Multivariate regression revealed factors positively correlated with future injectable use were index blepharoplasty or rhinoplasty, and history of preoperative neurotoxin injection (P < 0.05). Cosmetic facial injectables are an important consideration in achieving and maintaining optimal facial aesthetics. Their use, especially neurotoxins and facial fillers, has increased among patients postoperatively. These results highlight the contribution of injectable procedures in the context of multidimensional care for augmenting facial aesthetics.